$7.26 -0.05 (-0.68%)
12/3/2009 4:00 PM

MannKind Corp (MNKD)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer.

Recs

3
Member Avatar zzlangerhans (99.57) Submitted: 11/20/2008 1:08:18 PM : Outperform Start Price: $3.28 MNKD Score: +4.28

I remain long-term negative on Mannkind due to the well-established problems with inhaled insulins. However, the product has solid efficacy data which at least positions it for a favorable review from the FDA. I expect the FDA to set safety standards for Technosphere which are virtually impossible to overcome in terms of time and resources. In the near-to-mid-term I'm positive at this price point.

Report this Post 1 Comment
Member Avatar zzlangerhans (99.57) Submitted: 3/16/2009 2:50:14 PM
Recs: 0 Rec This

I'm going to bet on a pullback, and exit at virtually the same price I entered.

Report this Post

Featured Broker Partners